造血器疾患に合併した重症感染症に対するImipenem/Cilastatin sodiumの臨床的検討

巽 典之; 任 太性; 三宮 祐一; 陰山 克; 大藪 博; 赤坂 清司; 那須 芳; 米沢 毅; 冨永 信彦; 木谷 照夫; 田川 進一; 正岡 徹; 柴田 弘俊; 安永 幸二郎; 藤竹 英樹; 吉岡 宗; 堀内 篤; 長谷川 廣文; 中山 志郎; 永井 謙一; 矢部 博樹; 山口 延男; 寮 隆吉; 川越 裕也; 平田 充彦; 永井 清保; 武元 良整

doi:10.11553/antibiotics1968b.42.1065

THERAPEUTIC EFFECTS OF IMIPENEM/CILASTATIN SODIUM AGAINST SEVERE INFECTIONS IN PATIENTS WITH HEMATOPOIETIC DISORDERS

NORIYUKI TATSUMI, TAISEI NIN, YUICHI SANNOMIYA, TAKASHI KAGEYAMA, HIROSHI OHYABU, KIYOSHI AKASAKA, KAORI NASU, TAKESHI YONEZAWA, NOBUHIKO TOMINAGA, TERUO KITANI, SHINICHI TAGAWA, TOHRU MASAOKA, HIROTOSHI SHIBATA, KOHJIRO YASUNAGA, HIDEKI FUJITAKE, MUNETO YOSHIOKA, ATSUSHI HORIUCHI, HIROFUMI HASEGAWA, SHIRO NAKAYAMA, KENICHI NAGAI, HIROKI YABE, NOBUO YAMAGUCHI, RYUKICHI RYO, HIROYA KAWAGOE, MITSUHIKO HIRATA, KIYOYASU NAGAI, YOSHINOBU TAKEMOTO

Author information

NORIYUKI TATSUMI
Department of Laboratory Medicine, Osaka City University Medical School
TAISEI NIN
Department of Laboratory Medicine, Osaka City University Medical School
YUICHI SANNOMIYA
Department of Laboratory Medicine, Osaka City University Medical School
TAKASHI KAGEYAMA
The Second Department of Internal Medicine, Osaka Medical College
HIROSHI OHYABU
The Second Department of Internal Medicine, Osaka Medical College
KIYOSHI AKASAKA
Department of Internal Medicine, Osaka Red Cross Hospital
KAORI NASU
Department of Internal Medicine, Osaka Red Cross Hospital
TAKESHI YONEZAWA
The Second Department of Internal Medicine, Medical School, Osaka University
NOBUHIKO TOMINAGA
The Second Department of Internal Medicine, Medical School, Osaka University
TERUO KITANI
Department of Internal Medicine, Research Institute for Microbial Diseases, Osaka University
SHINICHI TAGAWA
Department of Internal Medicine, Research Institute for Microbial Diseases, Osaka University
TOHRU MASAOKA
Department of Internal Medicine, The Center for Adult Diseases
HIROTOSHI SHIBATA
Department of Internal Medicine, The Center for Adult Diseases
KOHJIRO YASUNAGA
The First Department of Internal Medicine, Kansai Medical University
HIDEKI FUJITAKE
The First Department of Internal Medicine, Kansai Medical University
MUNETO YOSHIOKA
The First Department of Internal Medicine, Kansai Medical University
ATSUSHI HORIUCHI
The Third Department of Internal Medicine, School of Medicine Kinki University
HIROFUMI HASEGAWA
The Third Department of Internal Medicine, School of Medicine Kinki University
SHIRO NAKAYAMA
Department of Immunohematology, Kobe Central General Hospital
KENICHI NAGAI
Department of Immunohematology, Kobe Central General Hospital
HIROKI YABE
Department of Immunohematology, Kobe Central General Hospital
NOBUO YAMAGUCHI
Department of Laboratory Medicine, School of Medicine, Kobe University
RYUKICHI RYO
Department of Blood Transfusion Service, School of Medicine, Kobe University
HIROYA KAWAGOE
Department of Internal Medicine, Osaka National Hospital
MITSUHIKO HIRATA
Department of Internal Medicine, Osaka National Hospital
KIYOYASU NAGAI
The Second Department of Internal Medicine, Hyogo College of Medicine
YOSHINOBU TAKEMOTO
The Second Department of Internal Medicine, Hyogo College of Medicine

JOURNAL FREE ACCESS

1989 Volume 42 Issue 5 Pages 1065-1076

DOI https://doi.org/10.11553/antibiotics1968b.42.1065

Details

Abstract

One hundred ninety-eight patients with severe infections associated with hematopoietic disorders were treated with imipenem/cilastatin sodium (IPM/CS), and the efficacy and safety of the drug were evaluated. The results obtained are summarized below.
1. Out of 182 patients in whom efficacies are evaluable, responses were excellent in 50 patients, good in 52, fair in 21 and poor in 59, and the efficacy rating was 56.0%.
2. The efficacy rating in 87 patients who had failed to respond to prior treatment with other antibiotics was 58.6%.
3. There were significant differences in efficacy ratings when patients were grouped according to differences the number of neutrophils after treatment, less than 100, 101,500 and over 501/mm³.
4. The eradication rate in 38 patients from whom causative organisms were isolated was 75.8%.
5. Out of 197 patients in whom the safety was evaluable, side effects were observed in 19 patients (9.6%) and abnormal laboratory test values in 15 (7.6%).

Corresponding author

Register with J-STAGE for free!